Samsung Bioepis has begun recruiting patients with paroxysmal nocturnal hemoglobinuria (PNH) in India for a phase 3 clinical study of its proposed eculizumab biosimilar, SB12, referencing Soliris.
Samsung Bioepis has begun recruiting patients with paroxysmal nocturnal hemoglobinuria (PNH) in India for a phase 3 clinical study of its proposed eculizumab biosimilar, SB12, referencing Soliris.
The double-blind, multicenter, crossover study will compare the efficacy, safety, pharmacokinetics (PK), and immunogenicity of SB12 with the reference eculizumab in approximately 50 patients with PNH, a rare, life-threatening disease of the blood characterized by destruction of red blood cells, presence of blood clots, and impaired bone marrow function.
Patients will be randomized to receive 600 mg of either the biosimilar or the reference eculizumab through intravenous administration every week for 4 weeks. Then, they will receive 900 mg of eculizumab for the fifth week, and 900 mg every 2 weeks until week 52. At week 26, patients initially randomized to the biosimilar will be switched to the reference, and those who initiated treatment with the reference will be switched to the biosimilar.
The primary outcome measures are hemolysis as measured by lactate dehydrogenase at week 26 in a parallel comparison and at week 52 by a crossover comparison. The study’s estimated completion date is July 2021.
In addition to PNH, the reference eculizumab is also approved by the FDA to treat atypical hemolytic uremic syndrome (a rare disease that causes abnormal blood clots to form in the small blood vessels in the kidneys), generalized myasthenia gravis (a rare, autoimmune, neuromuscular junction disorder), and, most recently, neuromyelitis optica spectrum disorder (NMOSD, a rare disorder of the central nervous system).
The European Medicines Agency’s Committee for Medicinal Products for Human Use has also adopted a positive opinion of eculizumab in for the treatment of NMOSD, and the European Commission will make a final determination on authorizing the drug for this fourth indication.
At least one other biosimilar developer is targeting the high-cost Soliris: Amgen’s proposed biosimilar, ABP 959, was recently shown in a phase 1 study to have similar PK and pharmacodynamics to the reference drug in patients 219 healthy volunteers. The proposed biosimilar also demonstrated similar safety and immunogenicity to Soliris.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.